SCHEMBL6475183

SCHEMBL6475183

Nc1ccc(Nc2ccc(CCc3ccc(Cl)c(Cl)c3)cc2)c(C(=O)O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.72
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
RECQL P46063 1/20 0.72
BLM P54132 1/20 0.72
SIRT2 Q8IXJ6 1/20 0.46
AKR1C3 P42330 5/20 0.44
AKR1C2 P52895 5/20 0.44
FFAR1 O14842 1/20 0.44
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 3/20 0.43
POLB P06746 2/20 0.43
LMNA P02545 1/20 0.43
CCR2 P41597 2/20 0.42
PNMT P11086 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
PTPRG P23470 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475344 0.94 MEN1 (0.64) TDP1MEN1KMT2ARECQLBLM
SCHEMBL6475930 0.86 MEN1 (0.73) TDP1MEN1KMT2ARECQLBLM
SCHEMBL6475983 0.85 MEN1 (0.72) TDP1MEN1KMT2ARECQLBLM
SCHEMBL6475798 0.85 MEN1 (0.72) TDP1MEN1KMT2ARECQLBLM
SCHEMBL6474443 0.84 MEN1 (1.00) TDP1MEN1KMT2ARECQLBLM
SCHEMBL29390191 0.84 MEN1 (1.00) TDP1MEN1KMT2ARECQLBLM
Potassium SCHEMBL6482258 0.82 MEN1 (0.97) TDP1MEN1KMT2ARECQLBLM
SCHEMBL6484252 0.82 MEN1 (0.97) TDP1MEN1KMT2ARECQLBLM
SCHEMBL6484243 0.82 MEN1 (0.97) TDP1MEN1KMT2ARECQLBLM
SCHEMBL6482249 0.82 MEN1 (0.97) TDP1MEN1KMT2ARECQLBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 TDP1 1124/4885MEN1 474/4885KMT2A 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.